Skip to main content
Springer Nature Link
Log in
Menu
Find a journal Publish with us Track your research
Search
Cart
  1. Home
  2. Treatments in Respiratory Medicine
  3. Article

Management of Influenza Virus Infections with Neuraminidase Inhibitors

Detection, Incidence, and Implications of Drug Resistance

  • Therapy In Practice
  • Published: 23 August 2012
  • Volume 4, pages 107–116, (2005)
  • Cite this article
Download PDF
Treatments in Respiratory Medicine
Management of Influenza Virus Infections with Neuraminidase Inhibitors
Download PDF
  • Jennifer L. McKimm-Breschkin1 

  • 329 Accesses

  • 50 Citations

  • Explore all metrics

Abstract

Although influenza vaccination remains the primary method for the prevention of influenza, efficacy may be limited by a poor match between the vaccine and circulating strains and the poor response of elderly patients. Hence, there is an important role for antiviral therapy in the management of influenza. While amantadine and rimantadine have been available for the treatment of influenza in some countries for several years, they are only effective against influenza A viruses, they can have neurological and gastrointestinal adverse effects, and resistant virus is rapidly generated. Neuraminidase inhibitors, a new class of drug, are potent and specific inhibitors of all strains of influenza virus, and they have minimal adverse effects. The greatest benefit is seen in those patients presenting <30 hours after development of influenza symptoms, those with severe symptoms or those in high-risk groups. In addition to treatment of the infection, both drugs are effective prophylactically and have been shown to limit spread of infection in close communities, such as families and in nursing homes. No resistant virus strains have been isolated from normal individuals treated with zanamivir. Resistant virus can be isolated from approximately 1% of adults and 5% of paediatric patients with influenza treated with oseltamivir. However, infectivity of mutant viruses is generally compromised. Governments spend millions of dollars on influenza vaccination campaigns; however, once influenza virus is circulating in the community, vaccination cannot limit the spread of disease. A greater promotion of the use of neuraminidase inhibitors for the treatment and prevention of influenza could have a significant impact on limiting its spread. This could result in saving millions of dollars, not only in direct costs associated with medical and hospital care, but also significant savings in indirect costs associated with the loss of productivity at work, school and home environments. For the benefit of all communities, there needs to be a greater awareness of the symptoms of influenza and the efficacy of neuraminidase inhibitors in disease treatment.

Article PDF

Download to read the full article text

Similar content being viewed by others

Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects

Chapter © 2017

Influenza and antiviral resistance: an overview

Article 13 February 2020

Antiviral Drugs for the Treatment and Prevention of Influenza

Article 10 August 2017
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

References

  1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179–86

    Article  PubMed  Google Scholar 

  2. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362: 1733–45

    Article  PubMed  CAS  Google Scholar 

  3. Ruest A, Michaud S, Deslandes S, et al. Comparison of the Directigen flu A+B test, the Quick Vue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003; 41: 3487–93

    Article  PubMed  CAS  Google Scholar 

  4. Nicholson KG. Managing influenza in primary care. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1999

    Google Scholar 

  5. Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health 2000; 3: 32–8

    PubMed  CAS  Google Scholar 

  6. Brocklebank JT, Court SD, McQuillin J, et al. Influenza-A infection in children. Lancet 1972; II: 497–500

    Article  Google Scholar 

  7. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. London: Blackwell Science Ltd, 1998: 358–72

    Google Scholar 

  8. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661–5

    Article  PubMed  CAS  Google Scholar 

  9. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–23

    Article  Google Scholar 

  10. Palese P, Tobita K, Ueda M, et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61: 397–410

    Article  PubMed  CAS  Google Scholar 

  11. Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr Top Microbiol Immunol 1985; 114: 177–255

    Article  PubMed  CAS  Google Scholar 

  12. Aoki F. Amantadine and rimantadine. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1995: 457–76

    Google Scholar 

  13. Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000; 160: 1485–8

    Article  PubMed  CAS  Google Scholar 

  14. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119–30

    Article  PubMed  CAS  Google Scholar 

  15. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocom- promised adults. Clin Infect Dis 1998; 26: 1418–24

    Article  PubMed  CAS  Google Scholar 

  16. Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 1992; 191: 541–9

    Article  PubMed  CAS  Google Scholar 

  17. Houck P, Hemphill M, LaCroix S, et al. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch Intern Med 1995; 155: 533–7

    Article  PubMed  CAS  Google Scholar 

  18. Ziegler T, Hemphill ML, Ziegler ML, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180: 935–9

    Article  PubMed  CAS  Google Scholar 

  19. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681–90

    Article  PubMed  CAS  Google Scholar 

  20. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000; 43: 3482–6

    Article  PubMed  CAS  Google Scholar 

  21. Stoll V, Stewart KD, Maring CJ, et al. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry (Mosc) 2003; 42: 718–27

    Article  CAS  Google Scholar 

  22. Kati WM, Montgomery D, Carrick R, et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother 2002; 46: 1014–21

    Article  PubMed  CAS  Google Scholar 

  23. Masuda T, Shibuya S, Arai M, et al. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg Med Chem Lett 2003; 13: 669–73

    Article  PubMed  CAS  Google Scholar 

  24. Honda T, Yoshida S, Arai M, et al. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Bioorg Med Chem Lett 2002; 12: 1929–32

    Article  PubMed  CAS  Google Scholar 

  25. Macdonald SJ, Watson KG, Cameron R, et al. Potent and long-acting dimeric inhibitors of influenza virus meuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother 2004; 48: 4542–9

    Article  PubMed  CAS  Google Scholar 

  26. Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother 2001; 2: 1671–83

    Article  PubMed  CAS  Google Scholar 

  27. McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin Pharmacother 2002; 3: 103–12

    Article  PubMed  CAS  Google Scholar 

  28. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001; 61: 263–83

    Article  PubMed  CAS  Google Scholar 

  29. Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs 2002; 62: 71–106

    Article  PubMed  CAS  Google Scholar 

  30. McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 2001; 35: 57–70

    Article  PubMed  CAS  Google Scholar 

  31. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir. Lancet 2004; 364(9436): 759–65

    Article  PubMed  CAS  Google Scholar 

  32. Hoffken G, Gillissen A. Efficacy and safety of zanamivir in patients with influenza: impact of age, severity of infections and specific risk factors. Med Microbiol Immunol (Berl) 2002; 191: 169–73

    Article  Google Scholar 

  33. Murphy KR, Eivindson APK, Stein WJ, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 2000; 20(5): 337–45

    Article  CAS  Google Scholar 

  34. US Food and Drug Administration, Center for Drug Evaluation and Research. NDA21-087 Tamiflu (Oseltamivir Phosphate) capsule [online]. Available from URL: http://www.fda.gov/cder/foi/nda/99/21087_Tamiflu.htm [Accessed 2003 Aug 6]

  35. Johnson RJ, Schweinle JE, Burroughs S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin Drug Invest 2000; 20(5): 327–36

    Article  CAS  Google Scholar 

  36. Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people’s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322: 577–9

    Article  PubMed  CAS  Google Scholar 

  37. Johnson RJ, Schweinle JE, Burroughs S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin Drug Invest 2000; 20(5): 327–36

    Article  CAS  Google Scholar 

  38. Silagy C, Watts R. Zanamivir, a new targeted therapy in the treatment of influenza: a patient perspective assessed by questionnaire. Clin Drug Invest 2000; 19: 111–21

    Article  CAS  Google Scholar 

  39. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127–33

    Article  PubMed  CAS  Google Scholar 

  40. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240–6

    Article  PubMed  CAS  Google Scholar 

  41. Wooltorton E. Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ 2004; 170: 336

    PubMed  Google Scholar 

  42. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J Infect Dis 2003; 187: 1000–9

    Article  PubMed  CAS  Google Scholar 

  43. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264–72

    Article  PubMed  CAS  Google Scholar 

  44. Tumpey TM, Garcia-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2002; 99: 13849–54

    Article  PubMed  CAS  Google Scholar 

  45. Leneva IA, Goloubeva O, Fenton RJ, et al. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001; 45: 1216–24

    Article  PubMed  CAS  Google Scholar 

  46. Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48: 101–15

    Article  PubMed  CAS  Google Scholar 

  47. CSIRO. CSIRO based drug effective against bird flu [online]. Available from URL: http://www.csiro.au/index.asp7.type=mediaRelease&docid=PrBird-Flu5&style=mediaRelease [Accessed 2004 Feb 20]

  48. CDC. Update on Influenza A(H5N1) and SARS: interim recommendations for enhanced US surveillance, testing, and infection control [online]. Available from URL: http://www.cdc.gov/flu/han020302.htm [Accessed 2004 Feb 12]

  49. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363: 617–9

    Article  PubMed  CAS  Google Scholar 

  50. Kuiken T, Rimmelzwaan GF, Van Amerongen G, et al. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003; 40: 304–10

    Article  PubMed  CAS  Google Scholar 

  51. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31–5

    Article  PubMed  CAS  Google Scholar 

  52. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families: Zanamivir Family Study Group. N Engl J Med 2000; 343: 1282–9

    Article  PubMed  CAS  Google Scholar 

  53. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186: 1582–8

    Article  PubMed  CAS  Google Scholar 

  54. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine- resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21: 700–4

    Article  PubMed  CAS  Google Scholar 

  55. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5: 205–13

    PubMed  CAS  Google Scholar 

  56. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43

    Article  PubMed  CAS  Google Scholar 

  57. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54

    Article  PubMed  CAS  Google Scholar 

  58. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep 2001; 27: 37–40

    PubMed  CAS  Google Scholar 

  59. Peters PHJ, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025–31

    Article  PubMed  Google Scholar 

  60. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors: a review. Antiviral Res 2000; 47: 1–17

    Article  PubMed  CAS  Google Scholar 

  61. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001; 49: 147–56

    Article  PubMed  CAS  Google Scholar 

  62. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257–62

    Article  PubMed  CAS  Google Scholar 

  63. Abed Y, Bourgault AM, Fenton RJ, et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 2002; 186: 1074–80

    Article  PubMed  CAS  Google Scholar 

  64. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40: 40–6

    PubMed  CAS  Google Scholar 

  65. Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-si-alyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77: 8418–25

    Article  PubMed  CAS  Google Scholar 

  66. Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6: 735–46

    Article  PubMed  CAS  Google Scholar 

  67. Jackson HC, Roberts N, Wange ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20: 447–54

    Article  CAS  Google Scholar 

  68. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41: 742–50

    Article  PubMed  CAS  Google Scholar 

  69. Molla A, Kati W, Carrick R, et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002; 76: 5380–6

    Article  PubMed  CAS  Google Scholar 

  70. Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818–27

    PubMed  CAS  Google Scholar 

  71. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug- resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348: 867–8

    Article  PubMed  Google Scholar 

  72. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103: 199–203

    Article  PubMed  CAS  Google Scholar 

  73. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002; 54: 99–111

    Article  PubMed  CAS  Google Scholar 

  74. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307–17

    Article  PubMed  CAS  Google Scholar 

  75. Herlocher ML, Truscon R, Elias S, et al. Transmission studies in ferrets of influenza viruses resistant to the antiviral oseltamivir. J Infect Dis 2004; 190(9): 1627–30

    Article  PubMed  CAS  Google Scholar 

  76. Vogel GE. Neuraminidase inhibitors in the management of influenza: experience of an outpatient practice. Med Microbiol Immunol (Berl) 2002; 191: 161–3

    Article  CAS  Google Scholar 

  77. Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 2003; 35: 52–8

    Article  PubMed  Google Scholar 

  78. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002; 113: 300–7

    Article  PubMed  Google Scholar 

  79. Da Silva PR, Nguyen VT, Hayward AC. Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care. J R Soc Med 2003; 96: 66–9

    Article  PubMed  Google Scholar 

  80. Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36Suppl. 1: 51–8

    Article  PubMed  CAS  Google Scholar 

  81. Cox RJ, Mykkeltvedt E, Sjursen H, et al. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine 2001; 19: 4743–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CSIRO Health Sciences and Nutrition, 343 Royal Parade, Parkville, Victoria, 3052, Australia

    Jennifer L. McKimm-Breschkin

Authors
  1. Jennifer L. McKimm-Breschkin
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Jennifer L. McKimm-Breschkin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKimm-Breschkin, J.L. Management of Influenza Virus Infections with Neuraminidase Inhibitors. Treat Respir Med 4, 107–116 (2005). https://doi.org/10.2165/00151829-200504020-00004

Download citation

  • Published: 23 August 2012

  • Issue Date: April 2005

  • DOI: https://doi.org/10.2165/00151829-200504020-00004

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Influenza
  • Influenza Virus
  • Sialic Acid
  • Oseltamivir
  • Amantadine
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Advertisement

Search

Navigation

  • Find a journal
  • Publish with us
  • Track your research

Discover content

  • Journals A-Z
  • Books A-Z

Publish with us

  • Journal finder
  • Publish your research
  • Open access publishing

Products and services

  • Our products
  • Librarians
  • Societies
  • Partners and advertisers

Our brands

  • Springer
  • Nature Portfolio
  • BMC
  • Palgrave Macmillan
  • Apress
  • Discover
  • Your US state privacy rights
  • Accessibility statement
  • Terms and conditions
  • Privacy policy
  • Help and support
  • Legal notice
  • Cancel contracts here

3.14.9.169

Not affiliated

Springer Nature

© 2025 Springer Nature